Which peptides are legal in 2026?

TL;DR

• "Legal" is four statuses, not one - approved drug, restricted compounding substance, review candidate, or grey-market "research use only".
• Approved today: semaglutide, tirzepatide, liraglutide, tesamorelin, bremelanotide (PT-141) and testosterone. Investigational: retatrutide, cagrilintide, kisspeptin.
• On 23–24 July 2026 an advisory committee recommended six of seven peptides for the 503A Bulks List - BPC-157, KPV, TB-500, MOTS-c, Semax and Epitalon - and voted against emideltide (DSIP).
• Recommended is not listed. As of 26 October 2026 no proposed rule has been published, none of the six is on the final Bulks List, and no interim policy has been issued. A draft "interim access" policy went to White House (OMB) review on 14 October 2026. Its text is not public, the review sets no legal deadline, and which peptides it would cover has not been disclosed, so even a peptide discussed at the July meeting may not be in it. Whether any specific peptide becomes easier to access is unestablished until a text is published.
• Removal from Category 2 is not promotion to Category 1 - a substance taken off it sits in no category at all.
• The FDA now treats "research use only" labelling as immaterial where the surrounding site context shows human-use intent - five warning letters dated 24 August 2026, posted 1 September.

Educational content, not medical advice. Status is US-focused and shifting fast in 2026 - verify against current FDA sources before relying on any single row. No doses or protocols appear.

Updated 26 October 2026: two new facts on the interim policy. The White House review entry describes it as a notice and sets no legal deadline, and the substances it would cover are not publicly disclosed. Retatrutide row updated for its Phase 3 readouts and planned Q1 2027 filing. Status dates moved to 26 October 2026; no row's legal status changes.

Updated October 2026: adds the 14 October 2026 submission of the FDA's draft interim peptide compounding policy to OMB/OIRA review - not issued, text not public, and if issued as expected (enforcement discretion) it would approve nothing, add nothing to the 503A Bulks List, and not cover research-use-only products, supplements or 503B. Status dates moved to 19 October 2026; no row's legal status changes.

Updated 28 September 2026: factual correction - Category 1 and the 503A Bulks List were previously treated as the same thing. They are not: Category 1 is the FDA's interim category for nominated substances under evaluation; the Bulks List is created by final rule. No row's status changes; none of the six recommended peptides is in either.

Updated 14 September 2026: adds the FDA's September enforcement sweep and, more importantly, the reasoning behind it - the agency treated "research use only" labelling as immaterial where the surrounding context showed the products were intended for people. That reasoning is the durable part of the news and it now sits in the "research use only" section, which previously argued the same point without a citable FDA position behind it.

Updated 14 September 2026: the table is now explicitly a September-2026 snapshot, and the "Recommended, but not listed" bucket has been corrected - coming off Category 2 does not confer Category 1 eligibility. A removed substance sits in no category at all. Nothing else about the legal picture has moved since the last review.

Updated September 2026: the July 23-24 advisory vote has now happened, and the table has been corrected from "under review" to the actual outcome: six recommended, one not. Adds the status correction that, as of 1 September 2026, no proposed rule has been published, the six are not on the final 503A Bulks List, and no interim enforcement policy has been announced. A recommendation did not change any row's legal status.

---

The single most confused question in this space is "is X legal?" - because people are asking one question that's really four. A peptide can be a fully approved prescription drug, a substance a pharmacy can compound (with limits), a candidate under FDA review, or an unapproved "research use only" chemical sold on the grey market. Ozempic and BPC-157 are both "peptides," and their legal reality could not be more different. This page sorts the common ones into those buckets. (For why the picture is moving right now, see the 2026 FDA reclassification explainer.)

The four buckets

• Approved drug. FDA-approved for a specific indication, available by prescription (e.g. semaglutide, tirzepatide). Off-label and aesthetic use is a separate conversation from approval.
• Compounding - now restricted. Compounded GLP-1s were widespread during the shortages; those shortages ended (tirzepatide Dec 2024, semaglutide Feb 2025), enforcement discretion lapsed in early 2025, and in April 2026 the FDA proposed to exclude semaglutide, tirzepatide and liraglutide from the 503B bulks list (the list outsourcing facilities can compound from); that is a proposal, not yet a final decision. Compounding is now largely limited to documented clinical-need modifications.
• Recommended, but not listed. Removed from the "Category 2" safety list in April 2026, then reviewed at the July 23–24, 2026 advisory-committee meeting, which recommended six of seven for the 503A Bulks List. That vote was non-binding. As of 26 October 2026 the FDA has published no proposed rule, the six are not on the final Bulks List, and no interim enforcement policy has been issued. Legally these sit exactly where they sat in June - the recommendation moved the debate, not the law.

The October development, and its limits. On 14 October 2026 HHS/FDA sent a draft "Interim Access Policy for Compounding Using Certain Peptides" to the Office of Information and Regulatory Affairs (OIRA, within the White House Office of Management and Budget) for review. It has not been issued and its text is not public, so which peptides, routes and conditions it would cover is unknown; press reports that BPC-157 would be included ran ahead of any published text. Law-firm analysis expects an interim enforcement-discretion policy, possibly placing certain peptides in Category 1 of the FDA's interim 503A bulks policy - the FDA signalling it would not plan to act against 503A pharmacies compounding them for individual patients, subject to conditions. Even in that form it would approve no product, change no statute and add nothing to the 503A Bulks List; covered peptides would remain unapproved drugs, and the policy could be narrowed or withdrawn without notice-and-comment. It would not cover research-use-only products, dietary supplements or the 503B outsourcing-facility channel, and it would not bind state boards of pharmacy or medicine. FDA funding currently runs under a temporary spending measure through 11 December 2026, which adds timeline risk.

Two facts added on 22 October 2026. First, the White House review entry describes the action as a notice (a policy statement, not a rule) and sets no legal deadline, so there is no date by which it must be issued, and it may never be. Second, the substances it would cover are not publicly disclosed. A peptide discussed at the July advisory meeting may not appear in the issued policy at all, so no reader should assume any particular row below is about to change. Until a published text says otherwise, every 🔬 row below is unchanged.

The part that gets reported wrong: removal from Category 2 is not promotion to Category 1. Category 2 is the "significant safety concerns" list - being taken off it only means the FDA is no longer asserting that concern as a bar to review. It does not move the substance into Category 1 (the FDA's interim category for nominated substances still under evaluation), it does not add it to the 503A Bulks List (a separate list created by final rule), and it does not make compounding lawful. A substance removed from Category 2 and not yet listed sits in no category at all, which is precisely the status of every 🔬 row in the table below.

• Research use only / grey market. Not approved, no clear compounding path. Sold with a "not for human use" disclaimer that shifts all liability to the buyer. This is where the real risk lives.

The status table

Legend: ✅ approved · 🔬 in the FDA compounding-review pipeline · 🧪 investigational (in trials) · ⚠️ research-only/grey-market · ◐ depends on route.

Read the "recommended" rows carefully. Recommended is not listed, and listed is not available. Six substances cleared a non-binding advisory vote in July; none of them is on the final 503A Bulks List, and none became lawful to compound as a result. The FDA must still publish a proposed rule, take public comment and issue a final rule - a sequence set out in what 503A compounding actually means - and it may decline at any stage. The interim policy now at OMB would not shortcut that sequence: enforcement discretion is a statement about where the FDA chooses not to act, not a listing.

What "research use only" actually means

It is the most misunderstood label in the industry, so be clear-eyed: "research use only, not for human consumption" is not a category of legal human medicine. It's a disclaimer that lets a seller move a compound while formally denying it's for people - which means no approval, no verified purity, no oversight, and full liability on whoever uses it.

As of September 2026, the FDA has said so in writing. On 1 September 2026 the agency posted a cluster of five warning letters, dated 24 August 2026, to online peptide sellers whose sites listed products including retatrutide, semaglutide, tirzepatide, elamipretide and tesamorelin. The operative finding is not the number of letters - it is the reasoning. The FDA held that the "research use only" and "not for human or animal consumption" statements on the labelling were immaterial where the surrounding context on the sellers' own websites established that the products were intended as drugs for human use. Context, in the agency's reading, includes things like human-facing usage instructions, weight-loss claims, and the sale of injection supplies alongside the vial.

That is the durable part, and it is worth stating plainly: the disclaimer is not a shield. It does not change what a product legally is, it does not change what the agency can act on, and - the point that matters most for a reader - it was never protecting the buyer in the first place. It exists to distance the seller. A shifting FDA review does not convert a grey-market vial into a safe or approved product. If a compound you care about is in the "under review" or "research only" column, the FDA category is not what protects you. What helps is knowing your own baseline health and talking honestly with your own doctor, who can look for problems in you as they happen. (How to tell a real clinic from a pill-mill.)

A note on where you are

This table is US-centric, and legal status varies by country. For our Southeast Asian market, approvals, import rules and advertising standards differ, and any therapeutic claim is subject to MAB requirements. Treat this as an orientation to how the system sorts peptides, not as legal advice for your jurisdiction.

FAQ

Are peptides legal? Some are FDA-approved drugs (semaglutide, tirzepatide, tesamorelin, bremelanotide, testosterone); many are investigational or sold "for research use only," which is not approval for human use. It depends entirely on the specific peptide - see the table.

Is BPC-157 legal in 2026? It was removed from the FDA's Category 2 list in April 2026, and on 23 July 2026 an advisory committee recommended it for the 503A Bulks List in a narrow, non-binding vote. That is not approval. As of 26 October 2026 no proposed rule has been published, BPC-157 is not on the final Bulks List, and no interim enforcement policy has been issued - so nothing about lawful access has changed, and it does not legalise grey-market sales. A draft interim policy has been at White House (OMB) review since 14 October 2026, with no legal deadline and no public list of covered substances; until its text is published, whether it covers BPC-157 at all is unknown, and even if it does it would cover only 503A pharmacy compounding for individual patients, not research-use-only products. (Details here.)

Why are compounded GLP-1s harder to get now? The shortages that allowed widespread compounding ended, enforcement discretion lapsed in early 2025, and in April 2026 the FDA proposed keeping semaglutide, tirzepatide and liraglutide off the 503B bulks list - so large-scale compounding is closing.

Is "research use only" a legal way to buy peptides? No. It's a liability disclaimer, not a human-use approval. It signals unverified product and no oversight - and in the warning letters it posted on 1 September 2026, the FDA treated that labelling as immaterial where the surrounding context showed the products were intended for human use. The words on the vial do not determine the legal category.

Where Vivre Labs fits

Vivre Labs offers compounds in several of the rows above, including semaglutide and tirzepatide (approved prescription medicines for weight management) and BPC-157 (investigational, recommended at the July meeting but not listed). Each compound page states its status. Whichever row a compound sits in, a category is not a safeguard, so we recommend starting with baseline bloodwork and talking it through with your own doctor.

Related reading

• The 2026 FDA peptide reclassification, explained · BPC-157 & KPV: the 2026 compounding decision · How to choose a peptide clinic · The honest peptide side-effects guide · PEG-MGF: the fifth name on the next FDA docket
• Are peptides legal now? The 2026 timeline, untangled - the three events behind the "it's legal now" headlines
• Part of The Complete Guide to Peptides

---

Educational content, not medical advice. Regulatory status is US-focused and changing through 2026 - confirm against current FDA sources at time of reading. International status varies; SEA-market claims are subject to MAB requirements. Peptide use is physician-directed.

References

• FDA Pharmacy Compounding Advisory Committee, July 23–24, 2026 meeting (7 peptides): six recommended (BPC-157, KPV, TB-500, MOTS-c, Semax, Epitalon), emideltide (DSIP) recommended against. Votes non-binding; FDA's own scientists recommended against all seven. · Status as of 26 October 2026: no proposed rule published, the six not on the final 503A Bulks List, no interim enforcement policy issued. · Draft "Interim Access Policy for Compounding Using Certain Peptides" submitted to OIRA/OMB for review on 14 October 2026; not issued, text not public; expected enforcement-discretion mechanism; would not cover research-use-only products, dietary supplements or 503B, and would not bind state boards - Holland & Knight, "Peptides at a Crossroads" (October 2026) (https://www.hklaw.com/en/insights/publications/2026/10/peptides-at-a-crossroads-what-wellness-providers-need-to-know); Buchanan Ingersoll & Rooney, 16 October 2026 (https://www.bipc.com/fda-submits-interim-peptide-compounding-policy-for-white-house-review-what-pharmacies-should-know); Becker's Hospital Review, 15 October 2026 (https://www.beckershospitalreview.com/glp-1s/hhs-sends-peptide-compounding-plan-to-white-house-5-things-to-know/); Quarles & Brady via Mondaq, 22 October 2026: OIRA entry describes the action as a notice, carries a RIN and sets no legal deadline; covered substances not publicly disclosed (https://www.mondaq.com/unitedstates/healthcare/1858180/fda-submits-interim-peptide-compounding-policy-for-white-house-review-what-pharmacies-should-know); OIRA review entry, RIN 0910-ZD94 (https://www.reginfo.gov/public/do/eo/neweomeeting?rin=0910-ZD94). · Retatrutide: Eli Lilly investor release, 23 July 2026, TRIUMPH-2 and TRIUMPH-3 met primary endpoints; US submission planned for Q1 2027. · Removal from Category 2 (April 2026, twelve substances) does not confer Category 1 eligibility - a removed substance sits in no category at all - Restorative Compounding (https://www.restorativecompounding.com/blog/fda-peptide-compounding-pcac-category-2-503a-bulks-list); Buchanan Ingersoll & Rooney (https://www.bipc.com/fda-pcac-recommends-six-peptides-for-the-503a-bulks-list-what-compounding-pharmacies-need-to-know). · Next PCAC docket, expected before end of February 2027: GHK-Cu, Melanotan II, cathelicidin (LL-37), dihexa acetate, PEG-MGF. · Background on FDA peptide regulation: Johns Hopkins Bloomberg School of Public Health (https://publichealth.jhu.edu/2026/how-the-fda-regulates-peptides). · FDA 503A/503B compounding policy updates and GLP-1 shortage resolutions (2024–2026); proposed 503B bulks-list removal of semaglutide/tirzepatide/liraglutide (April 2026). · FDA approval records: Egrifta (tesamorelin), Vyleesi (bremelanotide). · WADA Prohibited List (S2). · FDA warning letters to five online peptide sellers, letters dated 24 August 2026 and posted 1 September 2026; cited products across the letters include retatrutide, semaglutide, tirzepatide, elamipretide and tesamorelin. FDA treated "research use only" / "not for human or animal consumption" labelling as immaterial where website context established intended human use. (FDA warning-letter database; InsideHealthPolicy, FDA Steps Up Retatrutide Enforcement Against Online Peptide Sellers Following Eli Lilly Suit; Partnership for Safe Medicines, 8 September 2026.)